



**COMMONWEALTH OF KENTUCKY  
 CABINET FOR HEALTH AND FAMILY SERVICES  
 DEPARTMENT FOR MEDICAID SERVICES  
 PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.**  
 Thursday, October 17, 2024  
 1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
<a href="#">Join the meeting now</a>  Meeting ID: 220 301 349 522 Passcode: FBpdZz  <a href="#">Download Teams</a>   <a href="#">Join on the web</a>	+1-858-252-2734 (US Toll)  Phone Conference ID: 699 185 843#

## AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of April 2024 Meeting Minutes
  - b. Approval of July 2024 Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be Reviewed as Single Products:
    - i. Tryvio™ (Non-PDL)
    - ii. Iqirvo® (Bile Salts)
    - iii. Xolremdi™ (Non-PDL)
    - iv. Vafseo® (Erythropoiesis Stimulating Proteins)
    - v. Ohtuvayre™ (Chronic Obstructive Pulmonary Disease (COPD) Agents)
- V. New Therapeutic Class**
  - a. Muscular Dystrophy Agents
- VI. Therapeutic Classes with Recommended Changes**
  - a. Stimulants and Related Agents
  - b. Antimigraine Agents, CGRP Inhibitors
  - c. Colony Stimulating Factors
  - d. Growth Hormones
  - e. Acne Agents, Oral
  - f. Acne Agents, Topical
  - g. Antifungals, Topical
  - h. Antipsoriatics, Topical
  - i. Cytokine and CAM Antagonists



**VI. Therapeutic Classes with Recommended Changes (continued)**

- j. Gastrointestinal Motility, Chronic
- k. Immunologic and Genetic Immunomodulators, Atopic Dermatitis
- l. Multiple Sclerosis Agents
- m. Ophthalmics, Antihistamines
- n. Ophthalmics, Anti-Inflammatory Steroids
- o. Ophthalmics, Beta Blockers
- p. Otics, Anesthetics and Anti-Inflammatories
- q. Steroids, Topical

**VII. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> <li>• Anti-emetics &amp; Antivertigo Agents</li> <li>• Anti-Ulcer Protectants</li> <li>• Antibiotics, Topical</li> <li>• Anticholinergics and Antispasmodics</li> <li>• Antidiarrheals</li> <li>• Antiparasitics, Topical</li> <li>• Antipsoriatics, Oral</li> <li>• Antivirals, Topical</li> <li>• Bile Salts</li> <li>• H. Pylori Treatment</li> <li>• Histamine II Receptor Blockers</li> <li>• Immunomodulators, Asthma</li> <li>• Immunosuppressives, Oral</li> <li>• Laxatives and Cathartics</li> <li>• Ophthalmics, Mast Cell Stabilizers</li> <li>• Ophthalmics, Antibiotic-Steroid Combinations</li> </ul>	<ul style="list-style-type: none"> <li>• Ophthalmics, Antibiotics</li> <li>• Ophthalmics, Antivirals</li> <li>• Ophthalmics, Carbonic Anhydrase Inhibitors</li> <li>• Ophthalmics, Combinations for Glaucoma</li> <li>• Ophthalmics, Glaucoma (Other)</li> <li>• Ophthalmics, Immunomodulators</li> <li>• Ophthalmics, Mydriatic</li> <li>• Ophthalmics, NSAIDs</li> <li>• Ophthalmics, Prostaglandin Agonists</li> <li>• Ophthalmics, Sympathomimetics</li> <li>• Otics, Antibiotics</li> <li>• Proton Pump Inhibitors</li> <li>• Rosacea Agents, Topical</li> <li>• Spinal Muscular Atrophy</li> <li>• Ulcerative Colitis Agents</li> </ul>
---	---

**VIII. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. **2025 Meeting Schedule Pending**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.